{
  "nctId": "NCT02087449",
  "briefTitle": "Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population",
  "officialTitle": "A Prospective Multi-center Study on E1 Acetabular Liner in THA",
  "protocolDocument": {
    "nctId": "NCT02087449",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2015-01-22",
    "uploadDate": "2018-06-21T21:29",
    "size": 2508754,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02087449/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 100,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-02",
    "completionDate": "2024-12-12",
    "primaryCompletionDate": "2017-12",
    "firstSubmitDate": "2014-03-05",
    "firstPostDate": "2014-03-14"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nPatients will be included in this study if they received Ringloc acetabular system with E1 liner per the approved indications for use by KFDA in Korea. Specifically,\n\n1. Osteoarthritis\n2. Avascular necrosis\n3. Legg Perthes\n4. Rheumatoid Arthritis\n5. Diastrophic variant\n6. Fracture of the pelvis\n7. Fused hip\n8. Slipped capital epiphysis\n9. Subcapital fractures\n10. Traumatic arthritis Patients aged over 20 Patients with limited co-morbidity - ASA I - III\n\nExclusion Criteria:\n\nExclusion Criteria for this study should comply with the stated contraindications on package inserts of Ringloc acetabular system with E1 liner. These indications are stated below:\n\nAbsolute contraindications include: infection, sepsis, and osteomyelitis\n\nRelative contraindications include:\n\n1. uncooperative patient or patient with neurologic disorders who are incapable of following directions,\n2. osteoporosis,\n3. metabolic disorders which may impair bone formation,\n4. osteomalacia,\n5. distant foci of infections which may spread to the implant site,\n6. rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram, and\n7. vascular insufficiency, muscular atrophy, or neuromuscular disease.\n8. pregnancy",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "HHS score",
        "description": "Comparison in clinical outcomes scores between preoperative and various postoperative time points",
        "timeFrame": "1 year"
      }
    ],
    "secondary": [
      {
        "measure": "Hip Functions",
        "description": "Harris Hip Score at post follow-up visit",
        "timeFrame": "6 Months"
      },
      {
        "measure": "EQ5D",
        "description": "Standardised instrument for use as a measure of health outcome",
        "timeFrame": "6 Months"
      },
      {
        "measure": "Modified University of California Los Angeles (UCLA) Activity Score",
        "description": "It asks patients to rate their activity level from 1 to 10, with 1 defined as \"no physical activity\" and 10 defined as \"regular participation in impact sports\".\n\nThe UCLA scale has demonstrated construct validity, excellent reliability, and the best completion rates.",
        "timeFrame": "6 Months"
      },
      {
        "measure": "Radiographic Assessment",
        "description": "Radiographic Assessment at Immediate post-op(2 - 4 Weeks), 6 months, 1 year, 2 year, 5 year postop",
        "timeFrame": "Immediate post-op(2 - 4 Weeks)"
      },
      {
        "measure": "Hip Functions",
        "description": "Harris Hip Score at post follow-up visit",
        "timeFrame": "1 year"
      },
      {
        "measure": "Hip Functions",
        "description": "Harris Hip Score at post follow-up visit",
        "timeFrame": "2 years"
      },
      {
        "measure": "Hip Functions",
        "description": "Harris Hip Score at post follow-up visit",
        "timeFrame": "5 years"
      },
      {
        "measure": "EQ5D",
        "description": "Standardised instrument for use as a measure of health outcome",
        "timeFrame": "1 year"
      },
      {
        "measure": "EQ5D",
        "description": "Standardised instrument for use as a measure of health outcome",
        "timeFrame": "2 years"
      },
      {
        "measure": "EQ5D",
        "description": "Standardised instrument for use as a measure of health outcome",
        "timeFrame": "5 years"
      },
      {
        "measure": "Modified University of California Los Angeles (UCLA) Activity Score",
        "description": "It asks patients to rate their activity level from 1 to 10, with 1 defined as \"no physical activity\" and 10 defined as \"regular participation in impact sports\".\n\nThe UCLA scale has demonstrated construct validity, excellent reliability, and the best completion rates.",
        "timeFrame": "1 year"
      },
      {
        "measure": "Modified University of California Los Angeles (UCLA) Activity Score",
        "description": "It asks patients to rate their activity level from 1 to 10, with 1 defined as \"no physical activity\" and 10 defined as \"regular participation in impact sports\".\n\nThe UCLA scale has demonstrated construct validity, excellent reliability, and the best completion rates.",
        "timeFrame": "2 years"
      },
      {
        "measure": "Modified University of California Los Angeles (UCLA) Activity Score",
        "description": "It asks patients to rate their activity level from 1 to 10, with 1 defined as \"no physical activity\" and 10 defined as \"regular participation in impact sports\".\n\nThe UCLA scale has demonstrated construct validity, excellent reliability, and the best completion rates.",
        "timeFrame": "5 years"
      },
      {
        "measure": "Radiographic Assessment",
        "description": "Radiographic Assessment at Immediate post-op(2 - 4 Weeks), 6 months, 1 year, 2 year, 5 year postop",
        "timeFrame": "6 Months"
      },
      {
        "measure": "Radiographic Assessment",
        "description": "Radiographic Assessment at Immediate post-op(2 - 4 Weeks), 6 months, 1 year, 2 year, 5 year postop",
        "timeFrame": "1 year"
      },
      {
        "measure": "Radiographic Assessment",
        "description": "Radiographic Assessment at Immediate post-op(2 - 4 Weeks), 6 months, 1 year, 2 year, 5 year postop",
        "timeFrame": "2 years"
      },
      {
        "measure": "Radiographic Assessment",
        "description": "Radiographic Assessment at Immediate post-op(2 - 4 Weeks), 6 months, 1 year, 2 year, 5 year postop",
        "timeFrame": "5 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 17,
      "otherCount": 0,
      "totalCount": 18
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:59.244Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}